Podcasts about cancer research uk

We hear a lot about the pressures boys and young men are under and how many of them are looking to the online world - or manosphere as it's sometimes called - to find answers. Prompted by the drama Adolescence on Netflix, the topic has been in the news regularly in recent weeks. This week the Women and Equalities Select Committee heard evidence on the manosphere. Anita Rani is joined by Will Adolphy, who was a dedicated follower of the manosphere until, in his mid 20s, he had a breakdown. He went offline for five years and rebuilt his life. He is now a psychotherapist, coach, and goes to schools to speak about healthy masculinity.This week ITV has announced a shake up of the scheduling and production of its popular daytime shows including Lorraine, Loose Women and Good Morning Britain. Whilst Good Morning Britain will be extended, both Lorraine and Loose Women will see their number of shows cut. Entertainment journalist and expert on all-things TV Scott Bryan unpicks why this is happening.The Bombing of Pan Am 103 – is a new BBC factual drama series. Based on the true story of the bombing of a passenger flight over a small Scottish town of Lockerbie on 21 December 1988, in which 270 people were killed. Kathryn Turman was Assistant to a federal Senator at the time of the bombing. After the trial she joined the FBI where she founded the agency's first ever Victim Services Division. Her experience in the aftermath of the Pan Am bombing proved invaluable to the FBI's response to the 9/11 attacks, and she has aided victims and families throughout major moments in history including the Las Vegas shooting and the Boston marathon bombing. She discusses her mission to help victims, and what inspired her work in public service.Next month marks three years since the journalist and host of BBC's You, Me and the Big C podcast Deborah James - known to many as Bowel Babe - died, aged 40, five years after her stage four bowel cancer diagnosis. Bowel cancer is the third most common cancer type and cause of cancer death for women. Since the early 1990s, the incidence rate in women aged 25-49 has increased by almost 60%. Bowel cancer is treatable if diagnosed early. Heather James, Deborah's mother, is fulfilling a promise to her daughter and continuing with Deborah's awareness-raising work - she and Michelle Mitchell, Chief Executive of Cancer Research UK, are in the Woman's Hour studio.Presenter: Anita Rani Producer: Kirsty Starkey

In episode 107 I head north of the border to a stunning cemetery in Scotland's largest city. This city of the dead overlooks the city of the living, and its most prominent monument celebrates it's 200th birthday this year, predating the first burial here. With 50,000 of the city's dead buried here, it comes as no surprise that this place has long been rumoured to be haunted, but the best known supernatural entity said to lurk here in the darkness, is a vampire. A vampire which was so feared in the 1950s that school children descended on the graveyard with all manner of weapons, hell bent on putting an end to the monster. Let me tell you all about it, as you join me in asking, just how haunted is the Glasgow Necropolis? Support How Haunted? by subscribing and leaving a review. In July Rob will be taking on the "most difficult" walk in the North York Moors to raise money for Cancer Research UK. If you'd wish to sponsor us you can do so at justgiving.com/page/walk4john2025 Find out more about the pod at https://www.how-haunted.com and you can email Rob at Rob@how-haunted.com You can become a Patreon for as little as £1 a month. You can choose from three tiers and get yourself early access to episodes, and exclusive monthly episodes where Rob will conduct ghost hunts and you'll hear the audio from the night. You can even get yourself some exclusive How Haunted? merch. To sign up, and take advantage of a free seven day trial, visit https://patreon.com/HowHauntedPod Perhaps you'd rather buy me a coffee to make a one off donation to support the pod, you can do that at https://www.buymeacoffee.com/HowHauntedPod Music in this episode includes: Darren Curtis – Lurking Evil: https://youtu.be/3i0aVnpeppw " HORROR PIANO MUSIC " composed and produced by "Vivek Abhishek" Music link :https://youtu.be/xbjuAGgk5lU || SUBSCRIBE us on YOUTUBE: https://youtu.be/DQQmmCl8crQ || Follow on Facebook: https://bit.ly/33RWRtP || Follow on Instagram: https://bit.ly/2ImU2JV

The number of moles we have on our bodies largely depends on sun exposure. According to the Mayo Clinic, “Most people have 10 to 45 moles that appear during childhood and the teenage years.” Moles can vary in thickness, shape, colour, and they sometimes even have hair. They can pop up between your toes, on your scalp, on your earlobes or under your nails-anywhere really. Rest assured, most of the time these small brown spots are completely harmless, but still it's worth knowing some key info about moles. That's especially true given they can sometimes be cancerous, turning into a type of skin cancer called melanoma. According to Cancer Research UK, “there are around 16,700 new melanoma skin cancer cases in the UK every year.” What are moles actually made of ? Which genetic factors are at play then ? How can you tell if a mole is dangerous ? In under 3 minutes, we answer your questions! To listen to the last episodes, you can click here: ⁠Which bread is best for your health?⁠ ⁠Has the climate breakdown really begun?⁠ ⁠How small is a micropenis?⁠ A podcast written and realised by Joseph Chance. First broadcast the 03/04/2024 Learn more about your ad choices. Visit megaphone.fm/adchoices

Originally released for Patreon supporters in April 2024 I hope you enjoy this very special episode. In the 20th Patreon bonus podcast you join me on location at a 14th century pele tower in Northumberland, constructed during uncertain times when England was at war with Scotland, and being so close to the border required this tower to be fortified. But what would happen when, all alone, I stepped foot inside this tower? Would I hear the footsteps and voices heard here all too often, or perhaps I would be unfortunate enough to encounter the Preston Hound? Also you'll hear all about what happened to a listener when they visited during the summer of 2023. So tonight, join me as together we ask, just how haunted is Preston Tower? To get episodes such as this sooner, you can become a Patreon for £3 a month, and get yourself early access to episodes, and more exclusive episodes where Rob will conduct ghost hunts and you'll hear the audio from the night.  To find out more, or take advantage of a seven day free trial, head on over to https://patreon.com/HowHauntedPod Perhaps you'd rather buy me a coffee to make a one off donation to support the pod, you can do that at https://www.buymeacoffee.com/HowHauntedPod   Find out more about the pod at https://www.how-haunted.com and you can email Rob at Rob@how-haunted.com   In July Rob will be taking on the "most difficult" walk in the North York Moors to raise money for Cancer Research UK. If you'd wish to sponsor us you can do so at justgiving.com/page/walk4john2025   Music in this episode includes: "Darren Curtis - Demented Nightmare" https://youtu.be/g_O4kS9FP3k   " HORROR PIANO MUSIC " composed and produced by "Vivek Abhishek"   Music link : https://youtu.be/xbjuAGgk5lU SUBSCRIBE us on YOUTUBE: https://youtu.be/DQQmmCl8crQ Follow on Facebook: https://bit.ly/33RWRtP Follow on Instagram: https://bit.ly/2ImU2JV

In episode 106 we bring our time in an incredible, yet horrifying city in Massachusetts to a close. The impact of the 1692 witch trials is evident at every turn for anyone fortunate enough to visit, especially around Halloween, as one listener took the time to tell me about, as you'll hear. This might be the final part of a trilogy of episodes, but there's so, so much left to tell you as we've eight more scary places to visit, and go deep into the history and ghost stories. So without further ado, join me and let us ask together for the third and final time, just how haunted is Salem? Support How Haunted? by subscribing and leaving a review. In July Rob will be taking on the "most difficult" walk in the North York Moors to raise money for Cancer Research UK. If you'd wish to sponsor us you can do so at justgiving.com/page/walk4john2025 Find out more about the pod at https://www.how-haunted.com and you can email Rob at Rob@how-haunted.com You can become a Patreon for as little as £1 a month. You can choose from three tiers and get yourself early access to episodes, and exclusive monthly episodes where Rob will conduct ghost hunts and you'll hear the audio from the night. You can even get yourself some exclusive How Haunted? merch. To sign up, and take advantage of a free seven day trial, visit https://patreon.com/HowHauntedPod Perhaps you'd rather buy me a coffee to make a one off donation to support the pod, you can do that at https://www.buymeacoffee.com/HowHauntedPod Music in this episode includes: Darren Curtis – Lurking Evil: https://youtu.be/3i0aVnpeppw " HORROR PIANO MUSIC " composed and produced by "Vivek Abhishek" Music link :https://youtu.be/xbjuAGgk5lU || SUBSCRIBE us on YOUTUBE: https://youtu.be/DQQmmCl8crQ || Follow on Facebook: https://bit.ly/33RWRtP || Follow on Instagram: https://bit.ly/2ImU2JV

Jamie Hartmann-Boyce and Nicola Lindson explore new e-cigarette research and speak with Eden Evins from Massachusetts General Hospital and Harvard Medical School, about her randomized clinical trial on varenicline for youth vaping cessation. Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Professor Eden Evins from Massachusetts General Hospital and Harvard Medical School, Boston. In the April podcast Eden Evins discusses the findings of their new randomised clinical trial to evaluate the efficacy of varenicline for nicotine vaping cessation in 261 treatment seeking youth (16-24 years) who do not smoke tobacco regularly. This study has just been published in JAMA, April 2025 (DOI:10.1001/jama.2025.3810 NCT05367492). Professor Evins describes her interest in the high use of vapes among young people and the speed at which this increase to a different flavoured form of nicotine has occurred. Professor Evins and her team thought that varenicline, a pill based drug that is used for quitting smoking, could work for vaping cessation. She talks about the huge demand to take part in the study and how the team had to pause recruitment to keep up. She describes how young people were indignant, they had not expected to become addicted. Professor Evins says that when young people found they couldn't sit through a study session without needing to vape they were surprised and felt taken advantage of by marketers and these flavored products that they had thought were for fun. Their study funded by the National Institutes of Health in the US shows that the continuous abstinence rates in the last month of treatment (51% vs 14%) and at 6-month follow-up (28% vs 7%) are higher in the varenicline group than in the placebo group. This was a 12-week trial with 6 month follow up. Treatment-emergent adverse events did not differ significantly between groups. In summary varenicline, when added to brief cessation counselling, is well tolerated and promotes nicotine vaping cessation compared with placebo in youth with addiction to vaped nicotine. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and Interventions for quitting vaping review and shares the evidence from the monthly searches. Our search for the EC for smoking cessation review carried out on 1st April 2025 found 1 new ongoing study (NCT06789692) and 5 linked papers. Our search for our interventions for quitting vaping review up to 1st April 2025 found 3 new ongoing studies (NCT06862050; TCTR20250203006; NCT06885606), For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review of E-cigarettes for smoking cessation updated in January 2025 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub9/full For more information on the full Cochrane review of Interventions for quitting vaping published in January 2025 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016058.pub2/full This podcast is supported by Cancer Research UK.

Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised, phase 3 trial on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00034-1/fulltext?dgcid=buzzsprout_icw_podcast_28-04-25_lanhaeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Joining us this episode to discuss the highs and lows of parenting (and life) is Leanne Quigley. Leanne was the winner of the latest series of The Traitors UK 2025 and ambassador for Cancer Research UK. **TRIGGER WARNING** This episode contains discussions of IVF, C-sections and premature childbirth. Leanne is swapping the round table for the turn table as she takes on her next big challenge of running this year's Race for Life to raise vital funds for Cancer Research UK, a disease close to her heart. This campaign is deeply personal; in July 2024, just before she filmed The Traitors, Sophie Jones, Leanne's fiancée was diagnosed with stage three breast cancer. Through every step of Sophie's treatment, Leanne stood by her side, and now, after Sophie's all-clear in January, the couple are celebrating with a wedding on the horizon.  The former soldier and mum to two-year-old twin boys discusses parenting, her Race for Life challenge, the impact of cancer on her family, her time on The Traitors, and her plans for the future!  Parenting Hell is a Spotify Podcast, available everywhere every Tuesday and Friday. Please subscribe and leave a rating and review you filthy street dogs... xx If you want to get in touch with the show with any correspondence, kids intro audio clips, small business shout outs, and more.... here's how: EMAIL: Hello@lockdownparenting.co.uk Follow us on instagram: @parentinghell  Join the mailing list to be first to hear about live show dates and tickets, Parenting Hell merch and any other exciting news... MAILING LIST: parentinghellpodcast.mailchimpsites.com A 'Keep It Light Media' Production  Sales, advertising, and general enquiries: hello@keepitlightmedia.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Argyle Fives on kits.On Friday, 25th April, it is the Bobby Moore Fund for Cancer Research UK's annual Football Shirt Friday campaign. And as we have done for the last couple of years, Argyle are proud to support it.Therefore, the Argyle Fives team of Charlie Price, Rob McNichol and Kevin Nancekivell got together to discuss their favourite football shirts from Argyle history.Obviously, we all bleed green, but what shade of green? Do you prefer stripes or block colour? What about green and black or green and white. The constant throughout our history has been the colour green but there have been a wide variety of stripes that Argyle players have worn. But which ones will make it into the top five?Argyle Fives is also available to watch on Argyle TV - enjoy!

Claire Rowney joined Breast Cancer Now as Chief Executive Officer in 2024. In this episode, she talks about why she chose Breast Cancer Now, and her personal connection to breast cancer that happened while she was applying. Claire also talks about her career in charities including her time at Macmillan and Cancer Research UK, and outlines her ambitious plans for Breast Cancer Now to make sure that by 2050, everyone diagnosed with breast cancer not only lives, but lives well. You can listen to our previous episode we mention about breast cancer in South Asian communities here. We're Breast Cancer Now, the research and support charity. However you're experiencing breast cancer, we're here. For information and support, visit our website breastcancernow.org or phone our free helpline on 0808 800 6000 (UK only). Every episode is available to watch or listen to on the Breast Cancer Now website. You can also watch this episode on YouTube. Key Topics 0:09 Laura's thoughts on the episode ahead 1:46 Getting to know a bit more about who Claire is 3:59 Why Claire chose Breast Cancer Now 5:03 Claire shares how breast cancer affected her family 8:13 How Claire's personal experience of breast cancer has shaped her approach to running Breast Cancer Now 10:04 A day in the life of the CEO of Breast Cancer Now 14:09 Discussing Breast Cancer Now's 2050 vision 19:36 The challenges Breast Cancer Now faces 23:30 Claire's personal goals for Breast Cancer Now 24:28 Claire talks about the increasing rate of breast cancer diagnoses in the UK 26:36 Breast Cancer Now's work to improve diagnosis and outcomes for people from ethnic minority backgrounds 29:20 Claire outlines Breast Cancer Now's cutting-edge research 39:17 How Breast Cancer Now is raising awareness and understanding of secondary breast cancer 47:31 Claire's ambition for 5 years' time 48:20 How to get involved raising vital funds for Breast Cancer Now 51:53 What "living well" means to Claire

In this episode of The Cancer Researcher Podcast we interview Professor Charlie Swanton, Deputy Clinical Director of the Francis Crick Institute and Chief Clinician at Cancer Research UK on his research interests, the evolution of the field and how he turned round his failing PhD. Charlie also shares with us what he's looking forward to at the EACR Congress ahead of his Keynote Lecture and gives some excellent advice to early-career researchers on how to break away from the shyness that could hold some back from asking questions and networking at conferences.

Hi! and welcome to the Ninetieth episode of the Gaming Rules! Podcast.This episode is an audio recording of the Gaming Rules! YouTube Vlog from March 2025.  Paul discusses the games he played between 24th February 2025 through to 31st March 2025, gives details of his upcoming projects, and delivers a charity donation update.Link to the Cancer Research UK fundraiser: ⁠https://tilt.fyi/u73s5Aeo7O⁠Link to Mark Dainty's London Marathon Fundraiser: ⁠https://2025tcslondonmarathon.enthuse.com/pf/mark-dainty?utm_campaign=website&utm_medium=email&utm_source=enthuseIf you'd like to support the show, please consider becoming a Patreon by following the link ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠: https://www.patreon.com/GamingRulesLink to the gaming Rules! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ channel: https://www.youtube.com/GamingRulesVideosTimestamps00:00:00 Introduction & Opening Credits00:01:29 Galactic Cruise00:04:35 Avalon the Riven Veil00:08:43 War Room00:11:20 Men Nefer00:13:32 Free Ride USA/Freie Fahrt USA00:16:09 Tower Up00:17:53 The Lord of the Rings: The Fellowship of the ring trick taking game00:20:42 Skara Brae00:28:08 Fishing00:30:40 Lord of the Rings Day00:34:42 Agemonia00:37:26 Onward00:41:42 Ganz Schon Clever00:42:19 Flatiron00:43:30 Dune Imperium00:44:22 Project L & Square One00:47:36 Online Games00:50:11 Bonus Q&A with Will Brasher & Cuba Libre00:51:14 Upcoming Content00:56:49 Patreon Update01:00:54 Holiday 01:13:42 Charity Update01:15:05 Galactic Cruise Giveaway Winner01:17:34 Coming up in 202501:20:48 End credits

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Monserrat Conde from the University of Oxford. Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Dr Monserrat Conde from the Nuffield Department of Primary Care Health Sciences, University of Oxford. In the March podcast Monserrat Conde discusses the findings of the recent systematic review of electronic cigarettes and subsequent smoking in young people and an evidence and gap map. The systematic review aims to assess the evidence for a relationship between the use of e-cigarettes /vapes and subsequent smoking in young people under 30, and whether this differs by demographic characteristics. There is very low certainty evidence suggesting that e-cigarette use and availability are inversely associated with smoking in young people (i.e. as e-cigarettes become more available and/or are used more widely, youth smoking rates go down or, conversely, as e-cigarettes are restricted, youth smoking rates go up). At an individual level, people who vape appear to be more likely to go on to smoke than people who do not vape; however, it is unclear if these behaviours are causally linked. Monserrat discusses the differences in the information coming from the population studies compared to the individual level studies and notes that most studies are from high income countries, in particular from the US. To see the full review: https://doi.org/10.1111/add.16773 This podcast is a companion to the electronic cigarettes Cochrane living systematic review and Interventions for quitting vaping review and shares the evidence from the monthly searches. Our literature searches for the EC for smoking cessation review carried out on 1st March 2025 found 1 new study (DOI: 10.1016/j.drugalcdep.2024.112271), one new ongoing study (ACTRN12625000179437) and two records linked to studies included in the review. Our literature searches for the interventions for quitting vaping review carried out on 1st March 2025 found 2 new ongoing studies (NCT06832098, ACTRN12625000143426) and four records linked to studies included in the review. For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review of E-cigarettes for smoking cessation updated in January 2025 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub9/full For more information on the full Cochrane review of Interventions for quitting vaping published in January 2025 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016058.pub2/full This podcast is supported by Cancer Research UK.

We're back with the third season of That Cancer Conversation, the podcast from Cancer Research UK.Have you heard of cancer vaccines? Maybe you've seen a headline or two, but what is a cancer vaccine?In this episode, Sophie talks to Dr Heather Shaw, a skin cancer clinician and researcher at University College London, who is leading the first skin cancer (melanoma) vaccine trial in the UK. From what makes a cancer vaccine to discussing when we can see one in our clinics - we take a deep dive into the world of cancer vaccines.Discover more about cancer vaccines --> Cancer vaccines - where are we?If you enjoyed the episode, don't forget to subscribe and watch the new season all on our YouTube channel!Follow us on Instagram to stay updated and for more cancer stories visit Cancer News. Hosted on Acast. See acast.com/privacy for more information.

Zoologist, microbiologist and science champion Dr Bushra Schuitemaker has carved out a career in research and is determined to ensure young people from disadvantaged backgrounds know that science is for them too.Growing up in a single parent household in rural Essex, entitled to free school lunches, Bushra's stella science career is all the more remarkable because her local secondary school offered pupils no opportunities at all to take science A level courses.Positive she wanted to study zoology at university, she petitioned the school board, teachers and fellow pupils to get A level biology put on – which they did. Several years later, the school has full physics, chemistry and biology classes.Bushra's professional achievements, include working for Cancer Research UK at the Wellcome Sanger Institute, and now researching childhood obesity and puppy gut health at Biome9 and the Quadram Institute in association with the Guide Dogs organisation. And she partly puts her success down to thinking differently (she describes this as a superpower) because she has both dyslexia and dyspraxia.Read more and find extra links on the ProGRESS website show notes page hereYou might like to listen to:Sarah Ashworth, Researcher developer at University of Manchester S1 E11Rachel Warren, Professor of global change and environmental biology, The Tyndall Centre UEA S1 E7Matthew Halteman, Philosophy professor and animal and food ethicist, S3 E10Lydia Carrington, Sustainability manager Edgbaston Stadium S2 E1About ProGRESS:Host Sandra Kessell invites guests to discuss their pro- Green, Ethical, Sustainable and Socially responsible careers, courses and activities and asks for real-world insights into the paths and decisions that led to them.Original content © Sandra Kessell Original music © Lyze KessellFollow ProGRESS on LinkedInInstagram: @progress_green_careers_podcastEmail us: hello [@] mypro-gress.co.uk Hosted on Acast. See acast.com/privacy for more information.

In this episode, Dr Elle Wadsworth talks to three generations of tobacco/nicotine researchers: Dr Sarah Jackson and Emeritus Professors Martin Jarvis and Robert West, all from the Department of Behavioural Science and Health at University College London. They discuss a recent editorial, ‘The price of a cigarette: 20 minutes of life?' – why the message resonated, what was and is difficult to convey in tobacco research, and how the media coverage has changed for tobacco research over the years. · What the editorial is about [00:56]· Why the editorial resonated with the public and the media [01:40]· What messages were difficult to convey to the public [03:05]· Why the number of ‘20 minutes of life' has increased since the last estimate and why it is longer for women [07:43]· Choosing persuasive pieces and soundbites to communicate to the public [12:13]· The misinterpretation of research in the media and the difficulty in delivering nuance [14:08]· How the media coverage on tobacco and smoking has changed over the years [16:23]Dr Sarah Jackson is a Principal Research Fellow within UCL's Tobacco and Alcohol Research Group. She has authored >100 peer-reviewed articles on nicotine and tobacco. Her research activity focuses primarily on modelling population trends in smoking, evaluating smoking cessation interventions and policies, and advancing the evidence base on vaping. She is President of SRNT Europe, Senior Editor for Addiction, and Social Media Editor for Nicotine & Tobacco Research. Martin Jarvis is Professor Emeritus of Health Psychology at the Department of Behavioural Science and Health, UCL, having for many years worked with Michael Russell's smoking research group at the Institute of Psychiatry and then Cancer Research UK's Health Behaviour Unit. He has researched and published widely on tobacco smoking, with special interests in the role of nicotine, social and family influences on smoking, smoking cessation methods and passive smoking. He was awarded an OBE in 2002.Robert West is Professor Emeritus of Health Psychology at UCL. He specialises in behaviour change and addiction. He is former Editor-in-Chief of Addiction, and has acted as an advisor to the English Department of Health on tobacco control and currently advises the Public Health Wales Behavioural Science Unit. He helped write the blueprint for the UK's national network of stop-smoking clinics and is co-founder of the Capability-Opportunity-Motivation, Behaviour (COM-B) model of behaviour, the Behaviour Change Wheel framework for intervention development, and the PRIME Theory of motivation. Original article: The price of a cigarette: 20 minutes of life? https://doi.org/10.1111/add.16757 Authors praised the seminal work of the late Professor Michael Anthony Hamilton Russell (1932–2009). For further reading on the legacy of his landmark research, see here: https://doi.org/10.1111/add.14043The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal. The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information. Hosted on Acast. See acast.com/privacy for more information.

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Olivier Drouin from the University of Montreal, Canada. Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Dr Olivier Drouin. Dr Olivier Drouin is a Clinical Assistant Professor in both the Department of Paediatrics and Department of Social and Preventive Medicine at Université de Montréal. In the February podcast Olivier Drouin discusses his ongoing pilot randomized trial of a brief digital screening and intervention tool for parental and adolescents to address tobacco and electronic cigarette use, CanCEASE. This study takes place in paediatric medical care settings in Canada and is funded by the Canadian Institutes of Health Research. Their pilot study aims to demonstrate the feasibility and evaluate the preliminary effectiveness of the CEASE program for parental smoking cessation and its adapted version for adolescent smoking cessation and adolescent and parental vaping cessation. There is a strong need for effective and cost-effective smoking and vaping cessation interventions for parents and adolescents. If successful, this study will help inform the preparation of a fully powered randomized controlled trial of CEASE in Canada in these populations. Olivier Drouin discusses the importance of behavioural science in understanding the drivers of behaviour and health behaviour change, including the use of scientific method to understand rational and irrational behaviours, habit formation and the role of peer pressure and social norms. The pilot study discussed in this podcast by Chadi at al 2023 is DOI: https://dx.doi.org/10.2196/47978; NCT05366790. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and Interventions for quitting vaping review and shares the evidence from the monthly searches. Our literature searches for the EC for smoking cessation review carried out on 1st February 2025 found 2 new studies (Ikonomidis 2024 DOI: 10.1093/eurheartj/ehae666.3388; Kouroutzoglou 2024 DOI: 10.1093/eurheartj/ehae666.2955) and 6 papers linked to studies included in our review. Our catch-up search for our interventions for quitting vaping review up to 1st February 2025 found 7 new ongoing studies and 4 linked papers. For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review of E-cigarettes for smoking cessation updated in January 2025 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub9/full For more information on the full Cochrane review of Interventions for quitting vaping published in January 2025 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016058.pub2/full This podcast is supported by Cancer Research UK.

Bowel cancer is the fourth most common cancer in the UK, and experts believe poor diet is behind half of all cases. 肠癌是英国第四大最常见的癌症，而专家认为引起一半肠癌病例背后的原因都是不健康的饮食习惯。 Researchers at Oxford University, funded by Cancer Research UK, looked at data from more than half a million UK women over more than 16 years. It found that those with an extra 300 milligrams of calcium in their diets, equivalent to a large glass of milk a day, had a 17% lower risk of bowel cancer. 牛津大学研究人员在英国癌症研究基金会的资助下对 50 多万名英国女性在超过 16 年间的医学数据展开了研究。研究发现，每天在饮食中额外摄入 300 毫克钙的人，即等同于每天多喝一大杯牛奶，患肠癌的风险降低了 17%。 Researchers also said dark, leafy greens, white wholemeal bread and some non-dairy milks, which contain calcium, also had a protective effect. 研究人员还表示，同样含钙的深色绿叶蔬菜、全麦白面包以及部分种类的非乳制牛奶也具有一定的保护效果。

This very special episode is brought to you in paid partnership with Cancer Research UK. At the end of last year, myself, Richard Herring and Mark Steel sat down to have a frank, raw, funny and open conversation about something that has affected us all - cancer. We were later joined by Dr Sam Godfrey, the Science Engagement Lead at Cancer Research UK, who gave us invaluable insight into the incredible work Cancer Research UK are doing and why the future is looking bright. Disclaimer for this one - very strong language and discussions of cancer diagnosis and treatment are used throughout. Disclaimer: CRUK can only accept donations from countries where we are a registered charity. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). #ad Hosted on Acast. See acast.com/privacy for more information.

This week, Anna Taylor, Chief Executive of the Food Foundation discusses the latest annual Broken Plate report with Sue Pritchard, Executive Director of the Food Farming and Countryside Commission, Malcolm Clark, Senior Policy Manager at Cancer Research UK and Geoff Ogle, the Chief Executive of Food Standards Scotland. We also hear what Dr Chris Van Tulleken, Daniel Zeichner, Minister of State at the Department for Environment, Food and Rural Affairs, and one the Food Foundation's adult food ambassadors, Caroline Woolham think of the report. Hosted on Acast. See acast.com/privacy for more information.

This very special episode is brought to you in paid partnership with Cancer Research UK. At the end of last year, myself, Matt Forde and Mark Steel sat down to have a frank, raw, funny and open conversation about something that has affected us all - cancer. We were later joined by Dr Sam Godfrey, the Science Engagement Lead at Cancer Research UK, who gave us invaluable insight into the incredible work Cancer Research UK are doing and why the future is looking bright. Disclaimer for this one - very strong language and discussions of cancer diagnosis and treatment are used throughout. Disclaimer: CRUK can only accept donations from countries where we are a registered charity. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). #ad Become a member at https://plus.acast.com/s/rhlstp. Hosted on Acast. See acast.com/privacy for more information.

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and talk about the findings of their newly published Cochrane review of interventions for quitting vaping. Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research. Jamie and Nicola share the findings of their new Cochrane review of interventions for quitting vaping published in January 2025 and funded by Cancer Research UK (https://doi.org/10.1002/14651858.CD016058.pub2). This new review included nine studies in just over 5,000 participants. Studies tested nicotine replacement therapy, cytisine, varenicline, nicotine/vaping reduction and text message-based interventions. The review found that text-message-based interventions may help young people to stop vaping and that varenicline may help people to stop vaping when compared to no or minimal support. There was some promising evidence from a shorter study of cytisine. More information is needed on other interventions, on potential harms and on the effect on use of tobacco cigarettes. Twenty ongoing studies looking at a range of interventions were identified in the review. The motivation for the review and the press coverage is also discussed. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and Interventions for quitting vaping review and shares the evidence from the monthly searches. Our literature searches for the EC for smoking cessation review carried out on 1st December and 1st January found 3 new studies (Kale 2024 DOI 10.1101/2024.09.13.24313612; Pericot-Valverde 2024 DOI 10.1093/ntr/ntae260; Sifat 2024 DOI 10.1016/j.dadr.2024.100295) and 3 linked studies (DOIs 10.1016/j.heliyon.2024.e39695; 10.1111/add.16698; 10.1093/ntr/ntae223) For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review of E-cigarettes for smoking cessation updated in January 2024 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub8/full For more information on the full Cochrane review of Interventions for quitting vaping published in January 2025 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016058.pub2/full This podcast is supported by Cancer Research UK.

In this inspiring episode, Amy Burke talks about her journey as a beauty industry entrepreneur and how she didn't let her setbacks stop her. Starting from a spare bedroom with her six-week-old baby, Amy discovered her passion for lashes and transformed it into a thriving beauty empire. But her journey wasn't without challenges. While growing her salon and supporting others in the beauty industry, Amy faced one of the toughest battles of her life....breast cancer. Through resilience, determination, and sheer willpower, she continued to run her business, inspire her clients, and prove that nothing can hold you back from success. If you're a hair, beauty, or aesthetic business owner looking for motivation, practical tips, and a reminder that anything is possible - this episode is for you!

In this presentation, Prof. Robert Gilbert, Professor of Biophysics in the Nuffield Department of Medicine at the University of Oxford, explain how science, for the scientist, is a source of enchantment.Prof. Gilbert and his team work on molecular mechanisms underlying pathology in humans, specifically cancer and membrane pore formation and cell adhesion. Their work is funded by Cancer Research UK, the British Heart Foundation, the Medical Research Council, the Biotechnology and Biological Sciences Research Council, and the Wellcome Trust.In this presentation, he talks about: Scientific discoveries that have drastically changed the worldUnpacking the mechanistic lens of scienceHow delight and play are crucial for scientistsThe beauty of the form and fit of scienceOn aesthetic delight in scienceHow enchantment is essential to the scientific processTo learn more about Robert, you can find him at: Website: https://www.strubi.ox.ac.uk/research/professor-robert-gilbert Email: gilbert@strubi.ox.ac.ukThis episode is sponsored by:John Templeton Foundation (https://www.templeton.org/)Templeton Religion Trust (https://templetonreligiontrust.org/)Support the show

Join Emily Austen, EMERGE & SMARTER, Anant Sharma: Matter Of Form & Eva Alexandridis, 111SKIN to learn their best productivity tips to help you achieve your 2025 goals. On 27th January at 12.30pm GMT, Juliet Fallowfield, host of the How To Start Up entrepreneurship podcast, will moderate the panel.Book via this link. All ticket proceeds will be donated to Cancer Research UK. We'll be hearing how these leading entrepreneurs structure their time to ensure they are productive, how they avoid burn out & overcome challenges presented by entrepreneurship. Expect myth busting, frank conversation & an opportunity to ask your questions to the panel. The How To Start Up panel:Emily Austen: Founder & CEO of leading PR agency EMERGE and the author of SMARTER: 10 lessons for a more productive and less-stressed life, published in November. Having founded EMERGE in 2012, Emily has navigated entrepreneurship and discovered a tried and tested formula for avoiding unproductive busyness. Anant Sharma: Founder & CEO of Matter Of Form, a leading luxury brand and digital agency based in London. Having founded his company in 2009, Anant and his team work with some of the world's leading brands including Aman, Belmond & Knight Frank. Eva Alexandridis: Co-Founder of leading international skincare brand 111SKIN. Eva has not only built a globally recognised brand since 2012 but has practised the brand values in ensuring she also looks after herself as well as her business. About How To Start UpHow To Start Up is the entrepreneur's ultimate handbook. With experienced entrepreneurs offering valuable advice on what to do now, next or never when starting a company, the podcast regularly features in Apple Podcasts' entrepreneurial charts and sits within the top 25% of all podcasts globally. Listen to all previous episodes here. If you'd like to learn how to produce your own podcast, drop us a line hello@fallowfieldmason.com Text us your questions for future founders. Plus we'd love to get your feedback, text in via Fan MailSupport the show

E92 | In this week's episode of the Trade Legends podcast, Mark @MJTiffPlumbing sat down with plumber Nathan @NNPlumber to discuss his ongoing battle against Cancer (Non-Hodgkin lymphoma) whilst working as a tradesman within the construction industry. Chemotherapy and Construction. My Non-Hodgkin lymphoma battle as a PLUMBER. In the UK, the lifetime risk of developing cancer is approximately 1 in 2, according to Cancer Research UK. Nathan is a young plumber in the construction industry, and in early 2024 he noticed a little pain in his lower back. He thought little of it, as every tradesman in the construction industry gets a bad back from time to time. The pain failed to subside, and after many weeks of debilitating pain and endless doctors appointments, Nathan finally discovered what was causing him so much discomfort. He was diagnosed with Non-Hodgkin lymphoma (a cancer of the blood) and Nathan now knew that he had a real battle on his hands. He would have to stop working as a plumber, undergo 6 months of chemotherapy, and finally undergo an intense course of radiotherapy to destroy the tumours that had built up on his spine. Nathan now wants to educate people in the trades on a topic that he himself knew nothing about. As the earlier statement read, cancer will affect 1 in 2 people, so educating ourselves on the topic is paramount. Guest this week: Nathan @nnplumber (Insta, TikTok) Host: Mark @MJTiffPlumbing ⭐ Supported by Tradify | https://tradifyhq.com/ | @TradifyHQ

Lucinda Rouse and Andy Ricketts are joined by Michelle Mitchell, chief executive of Cancer Research UK, to discuss the charity's approach to fundraising, supporter engagement and advocacy.Michelle provides insight into the charity's ongoing data and digital transformation programme: a major investment that aims to personalise supporter engagement and raise the systems surrounding it to the same level as the world-leading research funded by CRUK.She stresses the importance of promoting innovation and experimentation to deliver the impact articulated in a clear organisational strategy.Also in the episode, Andy talks about Third Sector's latest Charity Pay Study, which identifies and ranks the sector's highest earners using data drawn from charities' accounts.Do you have stories of people whose lives have been transformed for the better thanks to your charity? If so, we'd like to hear them! All it takes is a short voice message to be featured on this podcast. Email lucinda.rouse@haymarket.com for further information.Tell us what you think of the Third Sector Podcast! Please take five minutes to let us know how we can bring you the most relevant, useful content. To fill in the survey, click here. Hosted on Acast. See acast.com/privacy for more information.

Powered by Peerr   In this week's episode Azmain shares his journey to building a following of over 400k+ across his social media where he shares health education content for the public and has collaborated with the likes of WHO, AstraZeneca, Cancer Research UK and more!

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Marathi Vojjala from New York University, Global Institute of Public Health, USA. Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Dr Marathi Vojjala from the Global Institute of Public Health, New York University, USA. In the November podcast Marathi Vojjala discusses her pilot randomised controlled trial (RCT) that aims to investigate the effects of switching to electronic cigarettes from combustible cigarettes and the potential acceptability of e-cigarettes or as a harm reduction strategy among individuals with chronic diseases who smoke. This study examines examining the potential of behavioural counselling paired with e-cigarettes versus nicotine replacement therapy (e.g. nicotine patches or gum) for achieving harm reduction and decreased combustible cigarette use. The findings from this pilot RCT hold significant implications for chronic conditions such as COPD, asthma, CAD, and peripheral arterial disease who smoke combustible cigarettes. The observed reduction in CPD and improvement in respiratory symptoms suggest that switching to e-cigarettes appears feasible and acceptable among those with chronic diseases. These results suggest that e-cigarettes may offer an alternative for individuals struggling to quit combustible cigarette smoking through existing pharmacotherapies. This study supports further exploration of switching to e-cigarettes as a harm reduction strategy among combustible cigarette users who have been unsuccessful at quitting by other means. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and shares the evidence from the monthly searches. Our literature searches carried out on 1st November found 1 new ongoing study (NCT06614504) & 2 linked papers (DOIs: 10.1111/dar.13953 & 10.1001/jamainternmed.2024.5196) For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review updated in January 2024 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub8/full This podcast is supported by Cancer Research UK.

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Marathi Vojjala from New York University, Global Institute of Public Health, USA. Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Dr Marathi Vojjala from the Global Institute of Public Health, New York University, USA. In the November podcast Marathi Vojjala discusses her pilot randomised controlled trial (RCT) that aims to investigate the effects of switching to electronic cigarettes from combustible cigarettes and the potential acceptability of e-cigarettes or as a harm reduction strategy among individuals with chronic diseases who smoke. This study examines examining the potential of behavioural counselling paired with e-cigarettes versus nicotine replacement therapy (e.g. nicotine patches or gum) for achieving harm reduction and decreased combustible cigarette use. The findings from this pilot RCT hold significant implications for chronic conditions such as COPD, asthma, CAD, and peripheral arterial disease who smoke combustible cigarettes. The observed reduction in CPD and improvement in respiratory symptoms suggest that switching to e-cigarettes appears feasible and acceptable among those with chronic diseases. These results suggest that e-cigarettes may offer an alternative for individuals struggling to quit combustible cigarette smoking through existing pharmacotherapies. This study supports further exploration of switching to e-cigarettes as a harm reduction strategy among combustible cigarette users who have been unsuccessful at quitting by other means. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and shares the evidence from the monthly searches. Our literature searches carried out on 1st November found 1 new ongoing study (NCT06614504) & 2 linked papers (DOIs: 10.1111/dar.13953 & 10.1001/jamainternmed.2024.5196) For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review updated in January 2024 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub8/full This podcast is supported by Cancer Research UK.

In this episode, we explore findings from a groundbreaking study recently published in Nature which revealed potential targets for bowel cancer prevention and treatment. The study provides the most detailed understanding yet of bowel cancer's genetic makeup. The research, which used data from the 100,000 Genomes Project identified over 250 genes that play a crucial role in the condition, driver genes and potential drug targets. Our guests discuss the potential impact of these findings on patient outcomes, screening for bowel cancer, and future prevention strategies. Helen White, Participant Panel Vice-Chair for Cancer at Genomics England is joined by Professor Ian Tomlinson, Professor of Cancer Genetics at the University of Oxford, Claire Coughlan, Clinical Lead for Bowel Cancer UK and consultant nurse in colorectal cancer, and Dr David Church, a clinical scientist fellow and a medical doctor specialising in oncology at Oxford University. "The people that were kind enough to donate samples to the 100,000 Genomes Project, they did so knowing that they almost certainly wouldn't benefit personally from their donation from their gift and that any benefits would be some way down the line and hopefully benefit others which is what we're seeking to realise now. But, you know, it's not a given when we treat people in the clinic so we're very, very grateful to those individuals." You can read more about the study in our colorectal cancer blog and our study findings news story. You can download the transcript or read it below. Helen: Welcome to Behind the Genes. Ian: One of the great hopes is that some of these new genes that we've found could be useful in preventing cancer and it doesn't necessarily matter that they're rare, even if they're only 1% of cancers, by using those and changing those in the normal individual before they have had cancer then we may be able to reduce that risk. So, there are lots of potential new targets for prevention that are coming through.  My name is Helen White and I'm the Participant Panel Vice-Chair for Cancer at Genomics England. Today I'm delighted to be joined by Professor Ian Tomlinson, Professor of Cancer Genetics at the University of Oxford, Claire Coughlan, Clinical Lead for Bowel Cancer UK and consultant nurse in colorectal cancer, and Dr David Church, a clinical scientist fellow and a medical doctor specialising in oncology at Oxford University.   Today we will be discussing a pioneering colorectal cancer study which using data from the 100,000 Genomes Project has uncovered new insights that could transform diagnosis and treatment for patients with bowel cancer. If you enjoyed today's episode we would love your support, please like, share and rate us on wherever you listen to your podcast.  Thank you for joining me today. We're going to be discussing the findings from a landmark study that has been published in nature. This study used data generously donated by people with bowel cancer who took part in the 100,000 Genomes Project giving us the most detailed look yet at the genetic makeup of colorectal cancer better known as bowel cancer. But before we get into that let's start by hearing from my guests. Could each of you please introduce yourselves.  Ian: I'm Ian Tomlinson, I work at the University of Oxford and most of my work is research into bowel cancer, it's genetic causes, the genes that are involved in actually causing the cancer to grow which may be different from genetic causes and also the use of that data to help patients whether guiding future treatments or potentially helping to prevent bowel cancer which would obviously be our optimum strategy to have the biggest impact on the disease and its incidents.   Claire: So, I'm Claire Coughlan, I'm the clinical lead for Bowel Cancer UK and my remit at the charity is to ensure that everything we do is clinically relevant and that we're providing services that meet the needs of those affected by bowel cancer and the educational needs of those health professionals that work with people affected by bowel cancer. I'm also a nurse consultant in colorectal cancer at Lewisham and Greenwich NHS Trust and I lead an urgent referral service there and also work with patients with late effects of bowel cancer.  David: I'm David Church, I'm a medical oncologist and Cancer Research UK advanced clinician scientist at the University of Oxford. I treat bowel cancer clinically and do research on bowel cancer and womb cancer including a lot of research using samples and data from Genomics England data service we're discussing today of course.  Helen: Great, thank you. Now let's turn to Claire to learn more about bowel cancer. Claire, can you share with us how common it is, how treatable it is and if there are any trends in terms of which groups of people are affected?  Claire: Of course, bowel cancer is a relatively common cancer, there are about 46,000 people each year in the UK diagnosed with bowel cancer so that is quite a large number. The thing that really drives us forward in bowel cancer is that the earlier stage you're diagnosed at the greater chance of survival. So, the figures for that are quite stark, we stage bowel cancer through stage one to 4 with one being the earliest stage and 4 being the most advanced.   If you are diagnosed with bowel cancer at stage one you have a 9 in 10 chance of being alive and well 5 years after your diagnosis of bowel cancer. And if you're diagnosed at the other end of the spectrum at stage 4 that drops to a 1 in 10 and should people survive after a diagnosis of stage 4, which more people than before do they will have had a lot of treatment for their bowel cancer so the burden of the treatment will also be with them after that. So, it's really important that we diagnose at the earliest possible stage which is why studies such as the one we're going to talk about today are so important.   We have noticed that there has been a slight increase in being diagnosed at a younger age. That said the latest statistic is 2,600 people were diagnosed under the age 50 in the UK last year so it's still a disease of older people, you still have a greater chance of getting bowel cancer as you get older but it's really, really important that we're aware that you can still get bowel cancer as a younger person.   Probably one of the most exciting things that has happened for bowel cancer of recent years is our bowel cancer screening programme and the age for that now has been brought down to 50, we're not quite there all over the country, but in the UK that is the aim that everyone will be screened for bowel cancer at the age of 50. So, yes it's a common disease and staging an early detection is vital. Helen: That's lovely Claire, thank you very much for that. David, turning to you could you please explain to us how bowel cancer typically develops? David: Yes, so we know compared with many cancer types quite a lot about how bowel cancer develops because the bowel is accessible to collect samples by a technique called endoscopy which is putting a camera into the bowel from which you can sample tumours or lumps. And so from genetic research done in the last 10 years we know that, or we've known for many years actually, for much longer, that cancer is a genetic disease, it's a disease caused by alterations in genes and particularly genes that control whether the cells in our bowel grow normally and die normally as they should do. And collectively when there are alterations in genes that regulate those processes you can have a cell or collection of cells which are able to grow without restraint and don't die when they should do which are some of the hallmarks of a cancer and they also require the ability to spread elsewhere in the body which is what kills people with cancer including bowel cancer. We know from research done in the last 10 to 15 years that some of the alterations in genes that can cause bowel cancer in combination occur very early in our life, even in the first and second decade of life, but don't cause cancer. The earliest detectable abnormality is typically a polyp which is a tumour, a lump within the bowel which is detectable and if removed is almost certainly cured by removal alone but if it's not detected then as that grows and acquires more alterations in genes then it can become a cancer and cancers develop the ability to invade the bowel wall, to spread to what we call lymph nodes or glands nearby and also to spread further afield, most commonly to the liver or to the lungs.   And for most people whom bowel cancer has spread to the liver or to the lungs or elsewhere unfortunately we're not able to cure their disease which as Claire has said is why there is such an importance in detecting cancers and pre-cancers as we call them so that the tumours are not actually cancerous but come before bowel cancer as early as possible.  Helen: Thank you David. Moving on to the study, Ian perhaps you can take this, in the study that you carried out my understanding is that the whole genome sequencing was used to investigate the genetic changes that lead to the development and growth of bowel cancer. And for this participants with bowel cancer in the 100,000 Genomes Project donated both a blood sample and a tumour sample while those with rare conditions only provided a blood sample, can you explain why that is?  Ian: As you said the study really looked at 2 quite separate arms albeit with a little bit of overlap as we'll see. So, one very important aim was to look at individuals, both children and adults, who had medical problems or other conditions that were unexplained but which had some features that suggested that they weren't necessarily inherited but there may be some variation in their genes that had caused them, and roughly half of the programme was dedicated to that.   Within that there was a small number of people who had a strong family history of bowel cancer or who had large numbers of polyps in the bowel and they were analysed in a separate part of the project from what we're mostly discussing. Within the cancer arm there was a collection really throughout England of patients who had most of the common types of cancer and a few with less common cancers.   And because when we're looking at genetic and related changes in cancers we need to make sure that those changes have actually occurred in the cancer as it started growing from its earliest stages with a small number of cells in the body that were slightly abnormal and then progressing. We need to look at what genetic variation the patient has in all the cells of their body. We don't want to look at patients and say that looks an interesting change, we may be able to use that if it's present in all of the normal cells in that patient's system.   We want to make sure the change is specific to the cancer itself and therefore we have to sequence both a sample probably taken from blood and a sample taken from the actual cancer. And in a way we subtract out the changes in the blood to identify the changes that have actually occurred in the cancer itself.  Helen: That's a very helpful explanation. Does this research show that there is a role for whole genome sequencing in clinical care?  Ian: I think my own view is it is all a question of cost. I think the advantages it provides it can assess multiple types of genetic change at once. It is relatively consistent across each cancer's genome between cancers, even between centres mean that it is the method of choice. There are undoubtedly developments that will happen in the future, maybe being able to sequence longer stretches of DNA in one go that will help the analysis.   And some of the computational methods are likely to develop to identify some of the slightly difficult to identify genetic changes but it ought to be the standard of choice. There are issues and potential difficulties in collecting the high-quality samples that have been needed from pathology laboratory and that will be difficult going forward with current budges and there are lots of challenges but ultimately it in some form has to be the method of choice. What wasn't done is to look at other molecule tests or essays, looking at RNA wasn't really done on a big scale as well as DNA and other changes to DNA apart from the genetic changes were not looked at.   So, there are certainly ways it could be improved if you had limitless money but I think the project, 100,000 Genomes has shown the whole genomes are. They have a lot of advantages and ultimately probably will be adopted by the NHS and similar organisations.  Helen: David, could you now tell us about the findings of this pioneering study and what impact these findings might have on people with bowel cancer in the future?  David: So, this is the largest study to date to analyse the entire genome of bowel cancer by some margin and the fact that we've done whole genome sequencing and in so many people it has really given us an unprecedented ability to identify the genetic alterations that drive bowel cancer. And within bowel cancer we've known for some time it is not a homogeneous entity that bowel cancer is not all created equal, that there are sub-groups of bowel cancer and we have been able to refine those over previous efforts. And I guess if you were to ask what the biggest take home for me from the study is it's just the complexity of the disease.   So, as we've mentioned we know that cancer is a genetic disease, that it's driven by genetic alterations, alterations in genes which regulate the growth of cells or the death of cells or the spread of cells. And we've known for many years that there is a modest number of genes which are commonly malfunctioning in bowel cancer and they would be in the tens to dozens really. But with this work we've hugely extended our understanding of the genes that drive bowel cancer and in fact we've discovered nearly 250 genes which are altered in bowel cancer and appear to drive the growth of the cancer.   Now we know that not all of those will be validated and by that I mean that there are associations that we find at the moment, not all of which will be biologically relevant but interpreted in the data we know a large number that are previously undiscovered are or we can be fairly confident of that. And one of the take homes from that is that many of these are only altered in a small fraction of bowel cancers.   So, rather than being perhaps half of bowel cancers or a third of bowel cancers there are a good number of genes, a very substantial number of genes, which are altered in say 3 to even 1% of bowel cancers. And if we think about how we go about targeting those and perhaps we'll come onto treatment later that poses really challenges for how we work and we would think about treating patients with bowel cancer who have those particular alterations in their cancers.  Helen: Thank you David, yes we'll come onto treatment shortly, but I think Claire has a question for you.   Claire: Yes, thank you. For me as somebody who works in this every day this is such an exciting and interesting study, particularly in light of what we said earlier about early detection and how critically important that is for improving outcomes in people with bowel cancer. So, in your view do you think this research could help shape future screening programmes or prevention strategies?  David: That's a great question, I suppose in terms of screening at the moment the majority of screening is done in the UK at least by testing for blood in the stool which is relatively non-specific so I'm not sure that that would be directly impacted by this research. But one area of early cancer detection that is perhaps more relevant is quite a lot of work including from Oxford actually in recent years looking at blood tests. So, testing blood samples for early detection of cancer whereby you can test for genetic alterations, fragments of DNA that have alterations from the bowel cancer or any cancer that circulates in the blood and that tends to rely on a small number of common alterations.   And with this data I could see that we might be able to refine those tests and in so doing improve our early detection of cancer but that would need quite some work before we could actually say look that had real potential I think. And in terms of prevention there are, I think Ian may want to come in on this, one or 2 sub-groups which you might think that you could try to prevent but of course that needs a lot of extra work really.   But I think we have some clues of the biology of bowel cancer and particularly some of the sub-groups where you might think well this drug would work better in terms of preventing that sub-group or that sub-group but that will need to be the subject of future study.  Helen: Ian, did you want to come in on that at all?  Ian: So, at the moment prevention is a fairly new way of helping to reduce the number of people with bowel cancer at the level of the whole population which is what we have in the UK above a certain age group as we heard from Claire earlier. The methods used, again as we heard, are screening for occult blood in the stool and then colonoscopy to identify either hopefully early cancers or polyps and remove those. But when we think about the methods that we use for preventing other diseases then normally where they're successful using a more easily delivered and I have to say less expensive method.   So, high blood pressure is treated to reduce the risk of cardiovascular disease and there are other diseases where those what you might call molecularly-based prevented strategies are coming in. We really lack that for bowel cancer in particular, it does happen for some other cancers, but one of the great hopes is that some of these new genes that we've found could be useful in preventing cancer. And it doesn't necessarily matter that they're rare, even if there are only 1% of cancers, by using those and changing those in a normal individual before they have had cancer then we may be able to reduce that risk.   So, there are lots of potential new targets for prevention that are coming through and as David said it is going to take a lot of work to work out which of those are deliverable and who will benefit. But we have quite a lot of opportunities in that space and although that may not be us that takes that forward, it may be, but it may not be. We think it is a lot of material for those interested in chemo prevention using drugs of cancer that they can work on and with luck deliver some new ways of preventing cancer that may be simply popping a pill every morning to take your risk right down to as close as zero as we can.  Helen: Thank you Ian. David, I think you had something to add here.  David: Thanks Helen. One area of prevention that we're really interested in Oxford and many others are is using the genetic alterations that we find in bowel cancers and other cancers as targets for vaccination. Now we know that gene alterations will cause abnormal proteins which while they might drive the cancer, make it grow or not die, can also be recognised by the immune system so the abnormal proteins can be recognised by the immune system as being foreign and as foreign they can be targeted by the immune system so the immune system will try and kill the cells carrying those alterations. And we know for some sub-sets of bowel cancers those alterations can be relatively predictable actually, they occur in quite a sizeable fraction of some sub-groups of bowel cancers.   And one area that we're particularly interested in at the moment and actively pursuing is using those targets where you need some additional work to demonstrate when they are particularly recognisable by the immune system. But to use these genetic alterations is potential targets for vaccination with the intention ultimately of preventing bowel cancer in at risk individuals or ideally in the full-term time the whole population. And we've received some funding from Cancer Research UK to pursue this line of research and we have a group working on this in Oxford and as I say many others do elsewhere.  Helen: Thank you David, yes I have a vested interest in this because my understanding is this work is aimed primarily at people with a genetic condition called lynch syndrome which predisposes the people who have inherited this gene change alteration to bowel cancer, womb cancer and other cancer. And I had womb cancer, as I think David you know, a few years back and discovered it was due to lynch syndrome and so it's really exciting that you're now looking at vaccinating preventing because yes I take aspirin every day, I have my colonoscopy every 2 years which have some effect on preventing these cancers but it's not 100% guaranteed. And I don't suppose it ever will be but having the vaccination in that armoury would be fantastic I think for future generations, it's very exciting and we look forward to hearing more about it.   Thank you Ian and David. I mean we've heard a lot there about preventing bowel cancer but I think moving back now to potential treatments, you know, we've heard from David how this study has shown a number of actionable findings but what are the next steps towards treatment? How can these findings be turned into real actions that will benefit those people diagnosed with bowel cancer in the future? Ian, perhaps you would like to pick up on this to start.  Ian: That step is one, you know, in which I'm not personally an expert but a lot of the newer treatments are based on the finding of so called driving mutations which are simply genetic changes that occur as the cancer grows and contribute to that growth and ultimately if it's not treated to the spread and dissemination of a cancer. And the fact that we have reported 250 which need validation but of which a large proportion are likely to be true drivers means that anyone of those can be a potential new target.   The criteria to be used for which of those mutations to pursue, which of those driver genes to chase up are quite complicated normally, depend on many things such as the interest of research groups and small and larger drug companies. And the similarity of those genes to other genes that have evolved and the processes that they make to go slightly wrong in the cancer.   So, there is also the issue that because these are uncommon, everybody talks a lot about personalised medicine or precision medicine, this would be truly precision or personalised medicine because a genetic change that was driving the cancer in only 1% of patients is obviously not a huge number of patients although bowel cancer is a common cancer so it's not a tiny number either. But it would mean investment at that level to benefit let's say 1 to 2% potentially of all patients with bowel cancer but I think that's a nettle we have to grasp. And I think our results are showing that most of the really common drug changes either have not yet been successfully targeted in treatment or are too difficult to target.   So, we're going to have to start looking at these less common genetic drivers and design strategies, inhibitors, you know, again that can be delivered to patients relatively straightforwardly in order to see whether they benefit the patients concerned. But there is this problem of getting enough patients enrolled in clinical trials where a change is only present in a relatively small proportion of all the patients with that cancer type.   Helen: Thank you Ian. Presumably if there is a relatively small number of patients the people who are looking at running these trials might be looking at perhaps international trials, would that be one way to go?  Ian: So, I think David can speak with more personal knowledge but there are international trial networks and there are collaborations along these lines already under way. I would hope that those could be made use of even more than they are already. There is, you know, a financial consideration for those developing new anticancer treatments which are, you know, high risk work and also the costs of setting up trials and enrolling people is not a trivial thing. So, I think those are hurdles that can be overcome but it would need a concerted effort to do that. Patients will play a major role in that and patient organisations as well as 100,00 Genomes and other similar projects.  Helen: Yes, thank you, David I don't know if you want to come in on that.  David: Yes, the challenge of testing therapies in small groups is a very real one and there is lots of interest at the moment in exploring alternatives to conventional clinical trials. And as we use more electronic patient records and we have pharmacy records so there is the potential to get those data from routine clinical practice and there is lots of investments and attention on that at the moment so called real world data which is always an interesting term as if patients in clinical trials aren't in the real world which of course they are.   But it's perhaps a little more cost effective sometimes in clinical trials, of course it does pose its own challenges in how you disentangle true treatment effect from other factors because there are many factors impacting on how long people with cancer live. But there is a lot of investment and effort going into that at the moment and it will be interesting to see how that develops over the coming years.  Helen: Turning to you Claire based on your experience how well do you think people with bowel cancer understand how genomes can help with their care and what support is currently available to them in this area?  Claire: I think the answer, as it is so often is, it's dependent on individuals and not just one individual. So, I think some patients are very motivated to know as much about this as possible and to understand and to know what the next steps may be in their own treatment that may be helped by this. Others don't want to have the same knowledge and want to be guided very much by their medical teams but I think oncologists obviously are at the forefront of this and we see at the charity … we have services at the charity that supports patients and we see lots of queries into our ask the nurse service where people have been given variable information about I suppose personalised medicine as Ian alluded to and how their very specific bowel cancer may be treated, so I think it varies from patient to patient.   There is support available so we have the ask the nurse service I alluded to. We have a brilliant patient forum actually and everybody in clinical practice will have seen this, patients often become more expert than anybody and they share advice and they're moderated forums that are a very safe place for people to ask questions where there is a moderator to ensure that it is made really clear that circumstances are individual.   And the same with the ask the nurse service because you don't have all the clinical information so it is about empowering people, so there is support available. I think the other thing that is really important is equipping specialist nurses with the knowledge that they need to support their patients. This is a really exciting area of evolution for bowel cancer particularly I think in all cancers at the moment but for bowel cancer I think things have changed fairly rapidly in recent years and specialist nurses really need support in knowing that they have up-to-date information to give their patients.   So, that's another challenge for us and any specialist nurses that might be listening to this podcast we have online education on genomics for specialist nurses. Just while we're talking about that and you mentioned lynch syndrome earlier, so there has been a lynch syndrome project as I'm sure you're aware where we're trying to get testing for lynch syndrome brought into local hospitals.   So, there was some funding via NHS England so that the testing be done at time of diagnosis, so a pre-test and then a final test if that's appropriate, for everybody diagnosed with bowel cancer to see if they have lynch syndrome. And in some trusts that has been done and in others it hasn't yet and the funding hasn't quite followed in the way that we need it to enable that to happen. It's vitally important, we think there are about 175,000 people in the UK with lynch syndrome and we only know about 5% of them. And this is a gene change that is an inherited gene change so we can do what we call cascade testing where we test family members and we can then employ preventative strategies to prevent people from developing bowel cancer.   So, it's a really important project, so I think as well as supporting patients with the information around the changes that are happening in this area we also need to ensure that we support the workforce and have investment there to enable the support of all the changes and the genomic landscape.  Helen: Absolutely Claire and so much resonates there with what you've said. Having myself had cancer discovered that was due to lynch syndrome, cascade testing offered to my family members so valuable. It turns out I inherited my change from my mum who is 83, has never had cancer, so I think that's a very good example of, you know, it doesn't necessarily mean that you will get cancer but actually on that point that you made about empowering patients I always have a right smile because there is my mum going off to all her other medical appointments because at 83 she sees quite a few people and she is always the one telling them about lynch syndrome and educating them because most of them haven't heard of it, so yes it's really, really important.   And that patient forum, you're probably aware of Lynch Syndrome UK, I don't have any involvement in that other than being a member but that is so valuable for people with a particular condition to go somewhere where they can talk to or listen to other people with a similar condition, really, really valuable.   Right, well I think circling back really to the 100,000 Genomes Project I think you touched on this earlier David but reflecting on what you and Ian have told us about your study what is it about the 100,000 Genomes Project bowel cancer dataset that made this work possible?  David: There are a few things, one of which and not least of which is the sheer size of the effort. So, to have whole genome sequencing for more than 2,000 individuals is previously unprecedented and we'll be seeing more of this now as we scale up our research efforts but at the inception of the project it was very, very ambitious and to be able to deliver that is a huge achievement. And the quality and breadth of the analysis is very strong as well.   And ultimately, you know, the former gives thanks to the people that were kind enough to donate samples to the 100,000 Genomes Project, they did so knowing that they almost certainly wouldn't benefit personally from their donation from their gift and that any benefits would be some way down the line and hopefully benefit others which is what we're seeking to realise now. But, you know, it's not a given when we treat people in the clinic so we're very, very grateful to those individuals.   And I think also to the scientists who worked incredibly hard over the last 5 years to deliver this work actually. So, having been part of the team and being lucky enough to be part of the team along with Ian we've had hugely motivated individuals that really have dedicated a large fraction of their working lives to delivering this project which I think is a fantastic achievement as well.  Helen: Thank you, thank you to all those participants who at a time when their lives probably were turned completely upside down by a cancer diagnosis were offered the chance to join the 100,000 Genomes Project and said yes. As you say most of them will have known that it won't have helped them but by donating their data, you know, it has allowed this work to happen and potentially it could change lots of people's lives in the future, so thank you to them.  Ian: Could I also just emphasise and agree with what David has said, I won't go through all the individuals by name, but if anybody wants to read the published report of the work there are several people on there, Alex Cornish is the first author, but many colleagues from an institute of Cancer Research, The University of Manchester, Birmingham, Leeds, other universities in London that all contributed, but also colleagues in the NHS and/or universities who recruited patients, collected samples, processed them etc and of course the people who did the preparation of the samples in genetics laboratories and actually did the sequencing and basic analysis too.   So, it is a truly huge effort across particularly all the cancer types which is particularly a complex collection given the fact the tumour is needed and a blood sample. It's quite difficult in a way to find a formal way of thanking them for all of this but without them it wouldn't have happened.  Helen: On that note I think we'll wrap up there. A huge thank you to our guests, Professor Ian Tomlinson, Clare Coughlan and Dr David Church for an enlightening discussion on the groundbreaking study published in nature. This research is set to reshape our understanding of colorectal cancer and pave the way for new possibilities in treatment and patient care.   If you would like to hear more like this please subscribe to Behind the Genes on your favourite podcast app. Thank you for listening. I have been your host, Helen White. This podcast was edited by Bill Griffin at Ventoux Digital and produced by Naimah Callachand. 

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Stephen Higgins from the University of Vermont Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Professor Stephen Higgins from the University of Vermont Tobacco Center of Regulatory Science, Burlington, USA. Professor Stephen Higgins uses the concepts and methods of behavioural economics and behavioural pharmacology to investigate tobacco, illicit drugs, and other health-related risk behaviours in vulnerable populations. In the October podcast Stephen Higgins describes his recent studies on reduced nicotine cigarettes and e-cigarettes in high-risk populations. Their three randomised clinical trials involved 326 participants. They found that decreases in cigarettes smoked daily, resulting from smoking cigarettes with reduced nicotine content, were significantly larger when adults from at-risk populations had access to e-cigarettes in their preferred flavours. Their study findings indicate that access to preferred flavoured e-cigarettes has the potential to enhance the effect of a nicotine-reduction policy on cigarette smoking in populations with psychiatric conditions or lower education level who are at greatest risk for smoking and associated harm. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and shares the evidence from the monthly searches. Our literature searches carried out on 1st October found: 2 new studies. The study by Higgins et al described on this podcast (DOI: 10.1001/jamanetworkopen.2024.31731) and DOI: 10.1093/ntr/ntae212. We also found 3 linked papers (10.2196/58260, 10.1111/add.16633, 10.1038/s41415-024-7850-5) For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review updated in January 2024 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub8/full This podcast is supported by Cancer Research UK

Our DNA is made up of 3000 million letters of code. They make up genes within our DNA and are responsible for how cells in our body grow and multiply. But what happens when something in that code goes wrong? Welcome to another episode of That Cancer Conversation, a podcast from Cancer Research UK that brings together the science and the stories behind cancer. In this episode, Sophie will be looking at the human genome and explore how changes in our DNA can increase our risk of getting cancer. Prof Mike Stratton, former director of the Wellcome Sanger Institute and a pioneer in cancer genetics, helps unpack this question and tells us how he and his team persevered to find the second BRCA gene (BRCA2) and its mutation. It's been 30 years since the discovery of the first BRCA gene, BRCA1. Sophie sits down with Maria, her sister, Chrissy, and their mother, all who were tested positive for the BRCA2 gene mutation. They discuss their cancer stories and how the life-changing discovery of the BRCA genes has affected them as a family. Read more cancer stories on Cancer NewsYou can donate to Cancer Research UK here Hosted on Acast. See acast.com/privacy for more information.

Figures from Cancer Research UK show that there are an average of nearly 57,000 new breast cancer cases detected each year in the country. It's the most common form of cancer, accounting for 15% of all cases. While the vast majority of breast cancer cases are in women, there are actually around 370 diagnoses in men each year too. That's right; men also have breast tissue around the nipples, so are also potentially susceptible. As we near the end of Breast Cancer Awareness Month, let's take a moment to discuss the phenomenon and raise awareness, to make sure any symptoms in men don't go overlooked. What are the symptoms men should look out for? What factors increase the risk? How is breast cancer in men treated? In under 3 minutes, we answer your questions! To listen to the last episodes, you can click here: What is Quantum medicine and is it a scam? What should I do with expired medicines? What is the medication Ozempic and why is it being used for weight loss? A podcast written and realised by Joseph Chance. Learn more about your ad choices. Visit megaphone.fm/adchoices

One time, scientists discovered something really strange in the rain—they found human cells! It happened when mysterious, red-colored rain fell in certain places, and people didn't know what it was. When scientists studied it under a microscope, they realized the red stuff contained tiny cells that looked a lot like human ones. This surprised everyone because you don't expect to find human-like cells falling from the sky! Some people thought it might be pollution or even something from space, but no one could figure out exactly where the cells came from. It's still a mystery that makes scientists scratch their heads! Credit: CC BY 4.0 https://creativecommons.org/licenses/... Oakville: by Rising From Ashes, https://commons.wikimedia.org/wiki/Fi... Diagram of a white blood cell: by Cancer Research UK, https://commons.wikimedia.org/wiki/Fi... Singapourfish: by Unknown author, CC BY-SA 3.0, https://creativecommons.org/licenses/..., https://commons.wikimedia.org/wiki/Fi... Animation is created by Bright Side. ---------------------------------------------------------------------------------------- Music from TheSoul Sound: https://thesoul-sound.com/ Check our Bright Side podcast on Spotify and leave a positive review! https://open.spotify.com/show/0hUkPxD... Subscribe to Bright Side: https://goo.gl/rQTJZz ---------------------------------------------------------------------------------------- Our Social Media: Facebook:   / brightside   Instagram:   / brightside.official   TikTok: https://www.tiktok.com/@brightside.of... Stock materials (photos, footages and other): https://www.depositphotos.com https://www.shutterstock.com https://www.eastnews.ru ---------------------------------------------------------------------------------------- For more videos and articles visit: http://www.brightside.me ---------------------------------------------------------------------------------------- This video is made for entertainment purposes. We do not make any warranties about the completeness, safety and reliability. Any action you take upon the information in this video is strictly at your own risk, and we will not be liable for any damages or losses. It is the viewer's responsibility to use judgement, care and precaution if you plan to replicate. Learn more about your ad choices. Visit megaphone.fm/adchoices

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Benjamin Toll, Medical University of South Carolina Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Professor Benjamin Toll, Medical University of South Carolina about his work and interventions to help people to quit vaping. Professor Benjamin Toll is a clinical psychologist, a professor of Public Health Sciences and Psychiatry, Co-Director of the Lung Cancer Screening Program, and Chief of Tobacco Cessation and Health Behaviors at the Hollings Cancer Center, and Director of the Tobacco Treatment Program at the Medical University of South Carolina. Ben Toll specialises in treatment of tobacco use disorders, alcohol use disorders, and improvement of health behaviours. In the September podcast Ben Tol describes how he became involved in this research field, about his smoking cessation work and about interventions to help people to quit vaping. Ben discusses some pilot studies of vaping cessation with Amanda Palmer and a study of varenicline for vaping cessation with Lisa Fucito. Ben talks about the importance of creating an evidence base to inform clinical practice guidelines for quitting vaping. At present there are very few studies looking at vaping cessation and Ben stresses the need for more studies in this field. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and shares the evidence from the monthly searches. Our literature searches carried out on 1st August & 1st September found: 1 new study (10.1093/ntr/ntae158), 5 new ongoing studies (DOI: 10.51847/c5AEETRrY9; DOI: 10.1186/s13722-024-00483-5; NCT06534905; NCT06543407; NCT06554873 ) & 3 linked papers. For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review updated in January 2024 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub8/full This podcast is supported by Cancer Research UK.

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Benjamin Toll, Medical University of South Carolina Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Professor Benjamin Toll, Medical University of South Carolina about his work and interventions to help people to quit vaping. Professor Benjamin Toll is a clinical psychologist, a professor of Public Health Sciences and Psychiatry, Co-Director of the Lung Cancer Screening Program, and Chief of Tobacco Cessation and Health Behaviors at the Hollings Cancer Center, and Director of the Tobacco Treatment Program at the Medical University of South Carolina. Ben Toll specialises in treatment of tobacco use disorders, alcohol use disorders, and improvement of health behaviours. In the September podcast Ben Tol describes how he became involved in this research field, about his smoking cessation work and about interventions to help people to quit vaping. Ben discusses some pilot studies of vaping cessation with Amanda Palmer and a study of varenicline for vaping cessation with Lisa Fucito. Ben talks about the importance of creating an evidence base to inform clinical practice guidelines for quitting vaping. At present there are very few studies looking at vaping cessation and Ben stresses the need for more studies in this field. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and shares the evidence from the monthly searches. Our literature searches carried out on 1st August & 1st September found: 1 new study (10.1093/ntr/ntae158), 5 new ongoing studies (DOI: 10.51847/c5AEETRrY9; DOI: 10.1186/s13722-024-00483-5; NCT06534905; NCT06543407; NCT06554873 ) & 3 linked papers. For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review updated in January 2024 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub8/full This podcast is supported by Cancer Research UK.

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Benjamin Toll, Medical University of South Carolina Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Professor Benjamin Toll, Medical University of South Carolina about his work and interventions to help people to quit vaping. Professor Benjamin Toll is a clinical psychologist, a professor of Public Health Sciences and Psychiatry, Co-Director of the Lung Cancer Screening Program, and Chief of Tobacco Cessation and Health Behaviors at the Hollings Cancer Center, and Director of the Tobacco Treatment Program at the Medical University of South Carolina. Ben Toll specialises in treatment of tobacco use disorders, alcohol use disorders, and improvement of health behaviours. In the September podcast Ben Tol describes how he became involved in this research field, about his smoking cessation work and about interventions to help people to quit vaping. Ben discusses some pilot studies of vaping cessation with Amanda Palmer and a study of varenicline for vaping cessation with Lisa Fucito. Ben talks about the importance of creating an evidence base to inform clinical practice guidelines for quitting vaping. At present there are very few studies looking at vaping cessation and Ben stresses the need for more studies in this field. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and shares the evidence from the monthly searches. Our literature searches carried out on 1st August & 1st September found: 1 new study (10.1093/ntr/ntae158), 5 new ongoing studies (DOI: 10.51847/c5AEETRrY9; DOI: 10.1186/s13722-024-00483-5; NCT06534905; NCT06543407; NCT06554873 ) & 3 linked papers. For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review updated in January 2024 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub8/full This podcast is supported by Cancer Research UK.

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Benjamin Toll, Medical University of South Carolina Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Professor Benjamin Toll, Medical University of South Carolina about his work and interventions to help people to quit vaping. Professor Benjamin Toll is a clinical psychologist, a professor of Public Health Sciences and Psychiatry, Co-Director of the Lung Cancer Screening Program, and Chief of Tobacco Cessation and Health Behaviors at the Hollings Cancer Center, and Director of the Tobacco Treatment Program at the Medical University of South Carolina. Ben Toll specialises in treatment of tobacco use disorders, alcohol use disorders, and improvement of health behaviours. In the September podcast Ben Tol describes how he became involved in this research field, about his smoking cessation work and about interventions to help people to quit vaping. Ben discusses some pilot studies of vaping cessation with Amanda Palmer and a study of varenicline for vaping cessation with Lisa Fucito. Ben talks about the importance of creating an evidence base to inform clinical practice guidelines for quitting vaping. At present there are very few studies looking at vaping cessation and Ben stresses the need for more studies in this field. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and shares the evidence from the monthly searches. Our literature searches carried out on 1st August & 1st September found: 1 new study (10.1093/ntr/ntae158), 5 new ongoing studies (DOI: 10.51847/c5AEETRrY9; DOI: 10.1186/s13722-024-00483-5; NCT06534905; NCT06543407; NCT06554873 ) & 3 linked papers. For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review updated in January 2024 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub8/full This podcast is supported by Cancer Research UK.

After defeats in GW4, Lee and Sam are in MUCH better spirits this week as Liverpool and Spurs both record home GW5 wins! LOADS to discuss in this weekend's big game at the Etihad as City leave it late to salvage a point against 10-man Arsenal. Elsewhere, Villa and Morgan Rogers leave it late against Wolves and Chelsea breeze past a woeful West Ham. We'll look back at all the weekend's action and plan ahead for GW6. A massive THANK YOU for all your support watching, liking and sharing our videos! _________________________      Support Sam on the Shine Night Walk for Cancer Research UK! https://fundraise.cancerresearchuk.or... _________________________         

Episode Summary:In this episode of Overlooked, host Golda Arthur speaks with Lucy Rudd, a biomedical scientist from the UK, who shares her powerful story of discovering a borderline ovarian tumor at just 28 years old. What began as a small lump quickly spiraled into a period of intense uncertainty, fear, and difficult decisions about her health and fertility. Lucy takes us through her journey of diagnosis, her experience with the healthcare system, and the emotional toll of living with the unknown.Hear how Lucy's medical background informed her understanding of the situation, but also how confusing and overwhelming the process became—even for someone with insider knowledge of the healthcare system. We also explore Lucy's struggle with fertility preservation, and the emotional aftermath of losing one ovary. Resources and Links:Learn more about borderline ovarian tumors - Cancer Research UK : https://www.cancerresearchuk.org/about-cancer/ovarian-cancer/types/borderlineResources for ovarian cancer in the UK: Target Ovarian CancerRelated Episodes:‘Diagnosis' from Overlooked Season 1SUBSCRIBE to the newsletter to get updates on the podcast: sign up at the banner on the website: www.overlookedpod.com. EMAIL US - get in touch with the show: hello@overlookedpod.comDISCLAIMER What you hear and read on ‘Overlooked' is for general information purposes only and represents the opinions of the host and guests. The content on the podcast and website should not be taken as medical advice. Every person's body is unique, so please consult your healthcare professional for any medical questions that may arise.

With Liverpool and Spurs both losing 0-1 at home this week, Lee and Sam are finding other reasons to be cheerful. That said, FPL wasn't too much to shout about either - although owners of Gabriel, Haaland and Ollie Watkins will disagree! Lee's questions whether Eze is still worth the price tag now he appears not to be on pens and we ask whether a corner has been turned by Erik ten Hag and Manchester United, or is this just another false dawn. A massive THANK YOU for all your support watching, liking and sharing our videos! _________________________      Support Sam on the Shine Night Walk for Cancer Research UK! https://fundraise.cancerresearchuk.org/page/sams-giving-page-35351  _________________________         

FREEDOM - LIBERTY - HAPPINESS SUPPORT DOC MALIK To make sure you don't miss any episodes please subscribe to either: The paid Spotify subscription here: ⁠https://podcasters.spotify.com/pod/show/docmalik/subscribe The paid Substack subscription here: ⁠https://docmalik.substack.com/subscribe You can GIFT a Substack subscription to a family or friend here: ⁠GIFT ABOUT THIS CONVERSATION: I want to thank Chris Connolly for making this podcast happen. Rachel has a First-Class Honours degree in Biological Sciences, specialising in Physiology from the University of Birmingham. She graduated from the College of Homeopathy, London, in 1997 and was in private practice as a homeopath until 2012. Rachel has lectured in homeopathy and medical sciences at various colleges in the UK and overseas. She held the post of Research Consultant for the Society of Homeopaths from 2008-2012 and was awarded an Honorary Fellowship in 2013 to acknowledge her outstanding contribution to Homeopathy. Rachel is currently the Chief Executive of the Homeopathy Research Institute (HRI), a UK-based charity dedicated to promoting high-quality research in homeopathy at an international level. The charity was founded by physicist Dr Alexander Tournier, who previously worked as an independent researcher for Cancer Research UK, conducting interdisciplinary research at the boundaries between mathematics, physics, and biology. In this conversation, we discuss homeopathy, particularly dispelling certain misconceptions, such as the fact that homeopathy is Evidence-Based. I hope you enjoy the conversation. Much love Ahmad x Links Website Homeopathy Research Instiutute IMPORTANT INFORMATION AFFILIATE CODES Hunter & Gather Foods ⁠Hunter & Gather Foods Use DOCHG to get 10% OFF your purchase with Hunter & Gather Foods. IMPORTANT NOTICE Following my cancellation for standing up for medical ethics and freedom, my surgical career has been ruined. I am now totally dependent on the support of my listeners, YOU. If you value my podcasts, please support the show so that I can continue to speak up by choosing one or both of the following options - ⁠Buy me a coffee⁠ If you want to make a one-off donation. Join my Substack To access additional content, you can upgrade to paid from just £5.50 a month Doc Malik Merch Store⁠ Check out my amazing freedom merch To sponsor the Doc Malik Podcast contact us at ⁠hello@docmalik.com⁠

Today, you'll learn about how when chimpanzees can't figure out how to do something they get their friends to teach them, a potential breakthrough in the fight against breast cancer, and how singing repairs the brain after a stroke. Chimpanzee Learning “Chimpanzees use social information to acquire a skill they fail to innovate.” by Edwin J. C. van Leeuwen, et al. 2024. “Like Humans, Bumblebees and Chimpanzees Can Pass on Their Skills to Form ‘Cumulative Culture'.” by Cristen Hemingway Jaynes. 2024. Breast Cancer Gel “Scientists make potential breast cancer breakthrough after preserving tissue in gel.” by Matthew Weaver. 2024. “Breast cancer statistics.” Cancer Research UK. n.d. Singing Brain Repair “Singing repairs the language network of the brain after a cerebrovascular accident.” University of Helsinki. 2024. “Vocal music boosts the recovery of language functions after stroke.” University of Helsinki. 2021. Follow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.

We begin a month of episodes from the Czech Republic, starting at a 13th century castle a little less than 50 miles from Prague, which has been the subject of debate since it was constructed as no one truly understands its purpose. Could this fortress actually be the last line of defense against nightmarish creatures from the depths of hell? Lets' find out together, as we ask how haunted is Houska Castle? August's Partner Podcast is Technically a Conversation, find out all about this excellent podcast at www.technicallyaconversation.com I walked 28 miles one day at the end of July to help Cancer Research UK, if you'd like to sponsor me you can do so at www.justgiving.com/page/walk4john2024  Support How Haunted? by subscribing and leaving a review. You can become a Patreon for as little as £1 a month. You can choose from three tiers and get yourself early access to episodes, and exclusive monthly episodes where Rob will conduct ghost hunts and you'll hear the audio from the night. You can even get yourself some exclusive How Haunted? merch. To sign up visit https://patreon.com/HowHauntedPod Perhaps you'd rather buy me a coffee to make a one off donation to support the pod, you can do that at https://www.buymeacoffee.com/HowHauntedPod Find out more about the pod at https://www.how-haunted.com and you can email Rob at Rob@how-haunted.com   Music in this episode includes: Darren Curtis – Lurking Evil: https://youtu.be/3i0aVnpeppw   " HORROR PIANO MUSIC " composed and produced by "Vivek Abhishek"   Music link :https://youtu.be/xbjuAGgk5lU || SUBSCRIBE us on YOUTUBE: https://youtu.be/DQQmmCl8crQ || Follow on Facebook: https://bit.ly/33RWRtP || Follow on Instagram: https://bit.ly/2ImU2JV  

In 2009, BRIAN HOLLEY was diagnosed with kidney cancer, and his left kidney was removed. There are now tumours in his pancreas, and one was recently found in his humerus and removed. Throughout this period, he has maintained symptom-free health largely through exercise, meditative practices and diet. This is the story of one man who continues to live a happy and active lifestyle while living with cancer and a book to give comfort and advice to others.  Brian is an engaging speaker living in the U.K and the author of .”What My Doctors Didn't Tell Me About Cancer: What You Can Do to Support and Enhance Your Cancer Treatment” We talk about how he first discovered he had cancer, how his doctor's approached treatment and how he became an advocate for himself in treating cancer with nutrition, supplements and meditation. Brian writes, “I've been living with kidney cancer since 2009. After a third operation in 2015, my cancer became metastatic, and 'visitors' took up residence in my lungs.  I turned down chemotherapy and am very fortunate to be going strong nearly ten years later. Another 'visitor' was evicted from my left humerus, and I now have 'unpaying guests' lodging in six locations in my body.  However, I'm able to lead an active and fulfilling life.  (At 84, I sing and play guitar in a band, undertake some gardening, serve on two committees and take several walks of two or three miles each week.) “Cancer is sneaky. We can live with it for months, even years, without knowing it's there. That's perhaps because cancer is not something we catch but something that happens to our own cells when their DNA is corrupted.”  And that is usually because of our lifestyle. “ . . . the first response to a problem should not be rejection but acceptance; acceptance of it and all its apparent implications. Yes, that sounds strange, but half the pain we suffer is in withstanding the idea that we should have to suffer at all.”    In early 2022, my wife, Elizabeth, suggested I keep a cancer diary, which by 2023 had turned into a book.  As I researched for the book, I was amazed at what I didn't know about cancer, having lived with it for so long.  I'd spent time volunteering for Macmillan and attending support groups) and discovered that was true for most of us.  I was shocked to find that my doctors didn't know some important things about cancer, too – how dangerous sugar could be, for instance. In 2023, with a broken humerus and prosthetic shoulder to deal with, the diary had grown into a book. I have continued my cancer diary, though, and will bequeath it to Cancer Research UK. Central to my book is my MEDS regimen: Mind, Exercise, Diet and Support.  I take my 'MEDS' every day.  My doctors are very dedicated and exceptionally hard-working. They all know a fantastic amount, but they can't know everything. There are many things we can do to support our immune systems and the treatment our doctors provide.   We need to be self-advocates: to ask pertinent questions about the whys and wherefores of our treatment  –  and impertinent ones too if necessary. I refused chemotherapy again in 2022.  It seems that I'm growing older faster than my tumours, which are growing big. I'm not at all afraid of dying, and I hope to die with cancer rather than of it. These last 15 years have been the richest time of my life.  

This time you join me on location in the wild, remote, Northumberland countryside, and we're on a monster hunt as I search for an eight-foot-tall creature covered in thick hair, with glowing eyes, who causes the ground to shake whenever it is present. In early 2002 the nation's imagination was captured by the notion that this country park could be home to a bigfoot-type creature. Of course the area has a ghost, in the shape of the Bonny Lass of Belsay, and I will tell you of some of the other terrifying creatures that are said to lurk within England's most northern county. Let's ask together, just how haunted is Bolam Lake Country Park? If you'd like to sponsor me to walk 28 miles in one day at the end of July to help Cancer Research UK you can do so at www.justgiving.com/page/walk4john2024  Support How Haunted? by subscribing and leaving a review. You can become a Patreon for as little as £1 a month. You can choose from three tiers and get yourself early access to episodes, and exclusive monthly episodes where Rob will conduct ghost hunts and you'll hear the audio from the night. You can even get yourself some exclusive How Haunted? merch. To sign up visit https://patreon.com/HowHauntedPod Perhaps you'd rather buy me a coffee to make a one off donation to support the pod, you can do that at https://www.buymeacoffee.com/HowHauntedPod Find out more about the pod at https://www.how-haunted.com and you can email Rob at Rob@how-haunted.com   Music in this episode includes: Darren Curtis – Lurking Evil: https://youtu.be/3i0aVnpeppw   " HORROR PIANO MUSIC " composed and produced by "Vivek Abhishek"   Music link :https://youtu.be/xbjuAGgk5lU || SUBSCRIBE us on YOUTUBE: https://youtu.be/DQQmmCl8crQ || Follow on Facebook: https://bit.ly/33RWRtP || Follow on Instagram: https://bit.ly/2ImU2JV  

Half the UK population will get cancer during their lifetime - and rates are rising. Each year, around 385,000 people in the UK are diagnosed and around 167,00 lives are lost to the disease. But scientists are developing new therapies, including personalised vaccines and targeted drugs, that attack cancer cells directly and more effectively. It's hoped this pioneering work could lead to better survival rates. David Aaronovitch and guests discuss promising developments in cancer care - to find out how significant they might be. Guests: Professor Charles Swanton, chief clinician at Cancer Research UK and deputy clinical director at the Francis Crick Institute; Dr Olivia Rossanese, Director of the Centre for Cancer Drug Discovery at the Institute of Cancer Research; Christian Ottensmeier, Professor of Immuno-Oncology at the University of Liverpool; Professor Alan Melcher, Consultant Clinical Oncologist at The Royal Marsden NHS Foundation TrustPresenter: David Aaronovitch Producers: Rosamund Jones and Sally Abrahams Sound engineers: Rod Farquhar and Neil Churchill Editor: Richard Vadon

You join me for a third, and final time, at a 4600 year old site, which contains the largest megalithic stone circle in the world. This time we take a look at one of the largest, and most impressive Neolithic burial sites in Britain. We don't know how many early humans were buried here, but we do know that this place appears to be haunted. So, lets' ask together one more time, just how haunted is Avebury? Huge thank you to Emma for joining me, and you can find all of her blogs, including the series about Avebury at www.weird-wiltshire.co.uk/ If you'd like to sponsor me to walk 28 miles in one day at the end of July to help Cancer Research UK you can do so at www.justgiving.com/page/walk4john2024  Support How Haunted? by subscribing and leaving a review. You can become a Patreon for as little as £1 a month. You can choose from three tiers and get yourself early access to episodes, and exclusive monthly episodes where Rob will conduct ghost hunts and you'll hear the audio from the night. You can even get yourself some exclusive How Haunted? merch. To sign up visit https://patreon.com/HowHauntedPod Perhaps you'd rather buy me a coffee to make a one off donation to support the pod, you can do that at https://www.buymeacoffee.com/HowHauntedPod Find out more about the pod at https://www.how-haunted.com and you can email Rob at Rob@how-haunted.com   Music in this episode includes: Darren Curtis – Lurking Evil: https://youtu.be/3i0aVnpeppw   " HORROR PIANO MUSIC " composed and produced by "Vivek Abhishek"   Music link :https://youtu.be/xbjuAGgk5lU || SUBSCRIBE us on YOUTUBE: https://youtu.be/DQQmmCl8crQ || Follow on Facebook: https://bit.ly/33RWRtP || Follow on Instagram: https://bit.ly/2ImU2JV  

Send us a Text Message.Cancer Research "Race For Life 2024"The boy's come live from Cancer Research Race for Life 2024 in Bury St Edmunds England.Patrick is running on behalf of Martin in the 5K race for Cancer Research UK's annual fundraising event.While Patrick slogs his way around the circuit, Martin will be making his way around the event speaking to different people supporting and participating this year.No matter how cancer affects us, life is worth Racing for. Enter Cancer Research UK's Race for Life and raise money for life-saving cancer research.There's a Race for you no matter your age, fitness level or reason for getting out there.A race for everyone – and we mean everyone. If you're new to running for charity 3k is a good distance to start with. Go solo or grab your family and friends. Walk, jog, run or take on the course, however, it suits you. Feel the power of moving with your fellow Race for Lifers and have fun! Looking for a new challenge? Take on a longer distance with no pressure and an unbeatable atmosphere.10 million Race for LifersOver 10 million of you have taken part in Race for Life events since 1994, fundraising for Cancer Research UK.£970m raisedTogether, you've raised over £970 million towards life-changing cancer research since it began more than 30 years ago.130,000 peopleWith your money, we've helped develop radiotherapy, which helps 130,000+ people with cancer in the UK every year.Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: Cancer Research UK, 2 Redman Place, London, E20 1JQ. You can contact the Race for Life team by calling 0300 123 0770.No Joke of the week this week.Finally, Patrick & Martin release news of their new Celebrity guests lined up next week.https://mywishcharity.co.ukhttps://stephen-john.co.uk#HeartTransplant#EbsteinsAnomaly#RareCondition#HealthJourney#LifeChangingDiagnosis#MentalHealth#Vulnerability#SelfCompassion#PostTraumaticGrowth#MedicalMiracle#BBCSports#Inspiration#Cardiology#Surgery#Podcast#Healthcare#HeartHealth#MedicalBreakthrough#EmotionalJourney#SupportSystem#HealthcareHeroes#PatientStories#CardiologyCare#MedicalJourney#LifeLessons#MentalWellness#HealthAwareness#InspirationalTalk#LivingWithIllness#RareDiseaseAwareness#SharingIsCaring#MedicalSupport#BBCReporter#HeartDisease#PodcastInterview#HealthTalk#Empowerment#Wellbeing#HealthPodcast#ChronicIllness#joepasquale#mywishcharity#comedy#funny#jokeCheck out our new website at www.whostomanddick.comCheck out our new website at www.whostomanddick.com